Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03638453
Other study ID # 18-294
Secondary ID 1K07CA211847-01
Status Completed
Phase N/A
First received
Last updated
Start date May 28, 2019
Est. completion date May 6, 2022

Study information

Verified date May 2023
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this new intervention is to make it easier for families to meet their basic household needs during childhood cancer treatment. The investigators want to learn how to best use PediCARE to help care for families.


Description:

The investigators know from previous studies that in addition to the basic worries about a child's cancer therapy, many families experience financial stress during their child's treatment. Financial stress may include difficulty paying the rent or mortgage, keeping the electricity or heat on, or putting food on the table. One of the investigators' research goals is to find ways to decrease the financial impact of treatment on each family, and make sure that financial stress does not impact a child's experience during treatment. The investigators have developed a new supportive care intervention called PediCARE (which stands for Pediatric Cancer Resource Equity) which provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through services such as Uber and Lyft). The investigators have evaluated the PediCARE support program in a small group of parents and used feedback from these parents to improve PediCARE. The investigators are now ready to do a feasibility study to find out whether the investigators can reliably deliver the PediCARE intervention to families. This type of study is called a feasibility study. The goal of this research study is to learn whether the investigators can successfully give the PediCARE support program to families-in other words, whether most families are interested in participating in a randomized study about the PediCARE support program and whether they use the PediCARE support program during the study. The investigators will also begin to understand whether the PediCARE support program reduces financial stress for families during therapy. Long-term, the investigators plan to test the PediCARE support program in a larger group of randomized families to answer the question of whether PediCARE reduces financial stress for families and improves outcomes during cancer treatment


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date May 6, 2022
Est. primary completion date February 10, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Day to 17 Years
Eligibility Inclusion Criteria: - Child newly diagnosed with cancer within 2 months; - Planned receipt of at least 4 cycles of chemotherapy at DFCI or UAB; - Parent/guardian screened positive for HMH*; - Child is <18 years at time of enrollment - In accordance with previous research1 families will be operationalized as having HMH for eligibility purposes if they report at least one of the below four concrete needs assessed during routine clinical care as follows: - Food insecurity. - Housing Insecurity. - Energy Insecurity. - Transportation Insecurity. HMH screening is performed as standard of care by site-specific psychosocial providers. Exclusion Criteria: - Child with diagnosis of relapsed cancer; - Child planned to receive fewer than 4 cycles of chemotherapy - Child planned to receive observation, radiation or surgical resection only; - Planned transfer of child to a non-DFCI or UAB facility for chemotherapy treatment; - Foreign national family receiving cancer care as an Embassy-pay patient; - Child is enrolled on DFCI 16-001 (due to ongoing embedded descriptive HMH study)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PediCARE
PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
Usual Care
Standard care per hospital guidelines.

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Charles H. Hood Foundation, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of recruitment At least 75 percent consent to randomization (e.g. recruitment). 6-months
Primary Feasibility of retention At most 20 percent attrition per arm. 6-months
Secondary Change in Household Material Hardship (HMH) in PediCARE vs Usual Care Change in HMH score (0-4) at intervention completion (6-months) compared to baseline. For each family, the difference between 6-month and baseline HMH scores will be categorized as improved (change score <0) or not improved (change score =0). For each arm, the proportion of families with improved HMH at the completion of the intervention (6-months) will be estimated along with a 90 percent exact CI. Based on prior data, the study team assumes a 30 percent resolution in HMH in UC, thus the 90 percent CI will be within ±24.9 percent. 6-months
Secondary Proportion of patients with at least one Emergency Department (ED) visit or Intensive Care Unit (ICU) in PediCARE vs Usual Care The proportion of patients with at least one ED and/or ICU visit will be estimated for each arm, as well as the difference between arms, along with a 90 percent confidence interval. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04340024 - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Active, not recruiting NCT03609177 - Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly N/A
Active, not recruiting NCT04591431 - The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Phase 2
Recruiting NCT06103669 - Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) N/A
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed NCT03736746 - Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals N/A
Recruiting NCT06397651 - A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live 1:1 Exercise Coaching and Personalised Digital Application on Cancer Survivors' Cost of Care N/A
Active, not recruiting NCT03850912 - Symptom Management Implementation of Patient Reported Outcomes in Oncology N/A
Completed NCT03392090 - SHARE (Sharing Goals and Preferences) Study N/A
Completed NCT03244826 - Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation N/A
Recruiting NCT03517332 - Circulating Tumor DNA Exposure in Peripheral Blood
Completed NCT03721926 - A Geriatric Oncology Collaborative Care Intervention for Older Adults With Advanced Cancer N/A
Active, not recruiting NCT03967379 - Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors N/A
Completed NCT05176860 - Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy N/A
Active, not recruiting NCT03674047 - Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Phase 2
Active, not recruiting NCT03752268 - Development of an Intervention to Enhance Cancer Pain Management N/A